Amanda Cass, PharmD, BCPS, BCOP, discusses strategies to manage the diarrhea that may occur as an adverse effect in patients treated with EGFR TKIs.
Amanda Cass, PharmD, BCPS, BCOP
Advertisement
Articles by Amanda Cass, PharmD, BCPS, BCOP
Advertisement
Latest Updated Articles
Dr. Cass on Managing Diarrhea in Patients Treated With EGFR TKIsOctober 21st 2022
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Breakthrough Therapy Designation to First-Line Daraxonrasib Plus Chemo in mPDAC
2
Bexobrutideg Produces High Response Rates Across Treatment Lines in CLL/SLL
3
FDA Accepts NDA for Bezuclastinib in Advanced Systemic Mastocytosis
4
Osimertinib Plus Gefitinib Suppresses Acquired EGFR Resistance Mutations in First-Line NSCLC
5